Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut J Ehrlich

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
The Lancet. Infectious Diseases|June 25, 2011
Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1)P Noel Barrett, Hartmut J Ehrlich
Critical Care Medicine|May 29, 2003
Activated protein C: more effective than nonactivated protein C?Hans Peter Schwarz, Hartmut J Ehrlich
Vaccine|January 27, 2009
The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infantsEva Maria Pöllabauer, Robert Petermann, Hartmut J Ehrlich
Expert Review of Vaccines|April 9, 2013
Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical developmentP Noel Barrett, Daniel Portsmouth, Hartmut J Ehrlich
Human Vaccines|October 3, 2006
Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posologyEva Maria Pöllabauer, Robert Petermann, Hartmut J Ehrlich
Travel Medicine and Infectious Disease|February 22, 2011
Re: Tick-borne encephalitis (TBE) trends in epidemiology and current and future managementHartmut J Ehrlich, Robert Petermann, P Noel Barrett
Current Opinion in Molecular Therapeutics|February 9, 2010
Developing cell culture-derived pandemic vaccinesP Noel Barrett, Daniel Portsmouth, Hartmut J Ehrlich
Vaccine|March 12, 2003
History of TBE vaccinesP Noel Barrett, Susanne Schober-Bendixen, Hartmut J Ehrlich
Critical Care Medicine|February 6, 2004
Only activated protein C treatment and not protein C has demonstrated an improvement in survival in severe sepsisS Betty Yan, Jean-Francois Dhainaut, Hans Peter Schwarz, et al.
Molecular Cancer Therapeutics|October 5, 2022
Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse ModelsDidier Scherrer, Noel Barrett, Luc Teyton, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
The Lancet. Infectious Diseases|June 25, 2011
Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1)P Noel Barrett, Hartmut J Ehrlich
Critical Care Medicine|May 29, 2003
Activated protein C: more effective than nonactivated protein C?Hans Peter Schwarz, Hartmut J Ehrlich
Vaccine|January 27, 2009
The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infantsEva Maria Pöllabauer, Robert Petermann, Hartmut J Ehrlich
Expert Review of Vaccines|April 9, 2013
Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical developmentP Noel Barrett, Daniel Portsmouth, Hartmut J Ehrlich
Human Vaccines|October 3, 2006
Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posologyEva Maria Pöllabauer, Robert Petermann, Hartmut J Ehrlich
Travel Medicine and Infectious Disease|February 22, 2011
Re: Tick-borne encephalitis (TBE) trends in epidemiology and current and future managementHartmut J Ehrlich, Robert Petermann, P Noel Barrett
Current Opinion in Molecular Therapeutics|February 9, 2010
Developing cell culture-derived pandemic vaccinesP Noel Barrett, Daniel Portsmouth, Hartmut J Ehrlich
Vaccine|March 12, 2003
History of TBE vaccinesP Noel Barrett, Susanne Schober-Bendixen, Hartmut J Ehrlich
Critical Care Medicine|February 6, 2004
Only activated protein C treatment and not protein C has demonstrated an improvement in survival in severe sepsisS Betty Yan, Jean-Francois Dhainaut, Hans Peter Schwarz, et al.
Molecular Cancer Therapeutics|October 5, 2022
Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse ModelsDidier Scherrer, Noel Barrett, Luc Teyton, et al.
Pageof 5